Transcell has pioneered an innovative and revolutionary animal-free testing strategy (patent protected) to implement as Digital Animal Replacement Technology (DART) – An Enterprise Solution. This technology is designed to be easily adopted by global bio/pharma companies at various stages of their discovery and development functions. It aligns with the recent FDA Modernization Act 2.0 and the international ban on testing cosmetics on animals, encouraging the use of non-animal cruelty-free testing platforms
Key features of this offering include:
DART: An Animal-Free Testing Alternative
DART: Upholding the Principles of 3Rs—Replacement, Reduction, and Refinement
Backed by Transcell’s breakthrough scientific innovation in animal-free testing strategy, Quantiphi, with strategic partnerships with technology leaders such as Google Cloud, Amazon Web Services, and NVIDIA, combined with its commitment to HIPAA compliance and ethical AI solutions, ensures that its practices are cutting-edge and compliant with industry standards.
No Comments
Sorry, the comment form is closed at this time.